Prof Landray is co-chief investigator of the RECOVERY trial, the national priority platform trial of potential treatments for patients hospitalised with COVID-19 in the UK. The trial was established at pace – moving from first draft protocol to first patient enrolled in 9 days and randomizing over 10,000 patients in the first 8 weeks. Five drugs are currently being compared with standard of care alone: lopinavir-ritonavir, dexamethasone, hydroxychloroquine, azithromycin, and tocilizumab. The protocol is deliberately streamlined to minimise the burden on clinicians and patients in the context of the ongoing pandemic. Full details, including the trial protocol, are available at www.recoverytrial.net Martin Landray is Professor of Medicine & Epidemiology at the Nuffield Department of Population Health, University of Oxford, UK. He has led a series of major clinical trials assessing treatments for cardiovascular and kidney disease. He is heavily involved in international efforts to develop improved clinical trial “Good Clinical Practice” guidelines and heads the Good Clinical Trials Collaborative supported by Wellcome, Bill & Melinda Gates Foundation, and African Academy of Sciences.